2024
Gene × environment effects and mediation involving adverse childhood events, mood and anxiety disorders, and substance dependence
Kranzler H, Davis C, Feinn R, Jinwala Z, Khan Y, Oikonomou A, Silva-Lopez D, Burton I, Dixon M, Milone J, Ramirez S, Shifman N, Levey D, Gelernter J, Hartwell E, Kember R. Gene × environment effects and mediation involving adverse childhood events, mood and anxiety disorders, and substance dependence. Nature Human Behaviour 2024, 8: 1616-1627. PMID: 38834750, DOI: 10.1038/s41562-024-01885-w.Peer-Reviewed Original ResearchAdverse childhood eventsSubstance dependenceMood/anxiety disordersAnxiety disordersChildhood eventsIndirect associationsGenetic riskExposure to adverse childhood eventsDevelopment of moodSubstance use disordersAssociations of adverse childhood eventsUse disorderMediation modelMood/anxietyDisorder factorsPolygenic scoresIndirect pathsDisordersEuropean ancestry individualsMoodTreatment approachesAnxietySelf-medicationEuropean ancestryLatent variables
2023
Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs
Roseberry K, Le-Niculescu H, Levey D, Bhagar R, Soe K, Rogers J, Palkowitz S, Pina N, Anastasiadis W, Gill S, Kurian S, Shekhar A, Niculescu A. Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Molecular Psychiatry 2023, 28: 2894-2912. PMID: 36878964, PMCID: PMC10615756, DOI: 10.1038/s41380-023-01998-0.Peer-Reviewed Original ResearchConceptsIndependent cohortCandidate biomarkersPsychiatric subjectsPersonalized approachConvergent functional genomics approachAnxiety disordersBest overall evidenceAdverse life eventsClinical worseningGene expression signaturesBlood biomarkersAnxiety medicationClinical utilityPsychiatric disordersHigh anxiety stateSevere anxietyUntreated anxietyDecrease qualityIndividual biomarkersAddiction potentialBiomarkersTop biomarkersAnxiety statesRisk predictionExpression signatures